Lantern Pharma (LTRN) 10-Q2023 Q1 Quarterly report

Filed: 9 May 23, 4:05pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: bearing, brain, caption, central, CNS, coverage, Deposit, depositor, economy, FDIC, formation, forward, GBM, guaranteed, higher, mid, move, notified, occurrence, PARP, pediatric, quarter, rare, resurgence, Starlight

Removed: academic, accessibility, addendum, AF, AFC, affinity, aggregate, agreed, amendment, analytical, animal, annum, API, Australian, authority, beginning, behalf, Berkshire, BioNumerik, bore, Califia, cGMP, chain, Chase, collaborate, commercially, conjugated, consequential, contract, covered, CRO, cumulative, DAC, deducted, deducting, deferred, deferring, Deficit, deliver, delivery, designated, digit, diligence, diligent, disrupted, disruption, domestic, double, eligible, enabling, enroll, entry, Europe, event, evidenced, exceed, exclusive, exclusively, extension, FCCC, February, fee, filing, fill, Fisher, Fox, fully, GMP, Good, guide, human, impacted, informed, ingredient, Institute, integrated, internally, international, IP, Japan, JPMorgan, Kentucky, lead, Lender, Lexington, licensed, linker, LLC, low, lower, maintenance, manufacture, manufactured, mature, Medicare, metastatic, milestone, million, mutation, NDA, negotiate, negotiated, network, obligated, obtained, October, operation, orphan, owed, past, Patheon, payload, percent, percentage, Piramal, PPP, predicted, produced, producing, protocol, range, RDDT, reaching, receivable, recently, recover, recoverable, recovered, recovering, redeemed, referred, registration, reimbursed, repayment, replaced, resume, royalty, satisfy, SBA, serve, sharing, Shilpa, single, Southwest, spread, stability, staffing, Sterile, sublicense, supplied, supply, SwRI, targeting, technology, Thermo, trademark, transferred, Translational, TriviumVet, uncertainty, underwriting, updated, upfront, validated, varying, Venture, vitro, vivoPharm, world

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Associated LTRN transcripts

LTRN similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Lantern Pharma Inc. (the “Company”) hereby certifies, to his knowledge, that:

	(1)	the accompanying Quarterly Report on Form 10-Q of the Company for the fiscal quarter ended March 31, 2023 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

	(2)	the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 9, 2023

/s/ Panna Sharma
Chief Executive Officer (Principal Executive Officer)